Figure 2 of Dailey, Mol Vis 2021; 27:191-xxx.


Figure 2. VEGFA165a strongly activates MAPK in primary HRMECs at doses where VEGFA165b has little effect. Activation of MAPK was measured with in situ immunofluorescence with a phosphospecific antibody (phospho-Thr202/Tyr204) for p44/42. A: Activation of MAPK at three time points after the addition of 1,000 pM VEGFA165a or VEGFA165b. Bar shows standard deviation. (t test, ***p<0.001 relative to untreated control, n=8 biologic replicates.) B: Dose–response curves for activation of MAPK. The median effective dose (ED50) was 73 pM for VEGFA165a and 1,015 pM for VEGFA165b. Bars indicate the 95% confidence interval for data fit to the four-parameter log-logistic function. n=4 biologic replicates per dose.